Abstract
Homologous recombination (HR), a key mechanism of DNA double strand break (DSB) repair, is commonly defective in high grade serous carcinomas (HGSC) of the ovary. BRCA1/2 mutations, as well as many other molecular and genetic defects, can lead to impaired HR. Treatment of HR-defective tumours with poly-ADP ribose polymerase (PARP) inhibitors, which block the key mechanism of single strand DNA breaks (SSB), exploits a therapeutic concept called “synthetic lethality”. Early experiences with PARP inhibitors in germline BRCA mutation carriers and sporadic HGSCs of the ovary have been promising. The development of PARP inhibitors for ovarian cancer is an area of active research. This article provides an overview of the molecular rationale for the use of PARP inhibitors and summarizes some of the key early clinical data of their use in ovarian cancer.
Keywords: Ovarian carcinoma, PARP inhibitors, high grade serous carcinomas, BRCA1 and BRCA2, Homologous recombination (HR), DNA double strand break (DSB) repair, single strand DNA breaks (SSB), synthetic lethality, mutation carriers, clinical data.
Current Pharmaceutical Design
Title:The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas
Volume: 18 Issue: 25
Author(s): Anna V. Tinker and Karen Gelmon
Affiliation:
Keywords: Ovarian carcinoma, PARP inhibitors, high grade serous carcinomas, BRCA1 and BRCA2, Homologous recombination (HR), DNA double strand break (DSB) repair, single strand DNA breaks (SSB), synthetic lethality, mutation carriers, clinical data.
Abstract: Homologous recombination (HR), a key mechanism of DNA double strand break (DSB) repair, is commonly defective in high grade serous carcinomas (HGSC) of the ovary. BRCA1/2 mutations, as well as many other molecular and genetic defects, can lead to impaired HR. Treatment of HR-defective tumours with poly-ADP ribose polymerase (PARP) inhibitors, which block the key mechanism of single strand DNA breaks (SSB), exploits a therapeutic concept called “synthetic lethality”. Early experiences with PARP inhibitors in germline BRCA mutation carriers and sporadic HGSCs of the ovary have been promising. The development of PARP inhibitors for ovarian cancer is an area of active research. This article provides an overview of the molecular rationale for the use of PARP inhibitors and summarizes some of the key early clinical data of their use in ovarian cancer.
Export Options
About this article
Cite this article as:
V. Tinker Anna and Gelmon Karen, The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002823
DOI https://dx.doi.org/10.2174/138161212802002823 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Polyoxometalates in Biomedicine: Update and Overview
Current Medicinal Chemistry Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Creating A Standard of Care for Fertility Preservation
Current Women`s Health Reviews Hedgehog Signaling in the Normal and Neoplastic Mammary Gland
Current Drug Targets MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved
Current Pharmaceutical Design The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science A proteomics based approach for the identification of gastric cancer related markers
Current Pharmaceutical Design Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Curbing the Deregulation of Glycosylation in Tongue Carcinoma Cells with Natural Compounds
Anti-Cancer Agents in Medicinal Chemistry The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds A Comprehensive Insight Towards Pharmaceutical Aspects of Graphene Nanosheets
Current Pharmaceutical Biotechnology Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry